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Abstract
Due to their ease of isolation, differentiation capabilities, and immunomodulatory properties, the therapeutic
potential of mesenchymal stem cells (MSCs) has been assessed in numerous pre-clinical and clinical settings.
Currently, whole pancreas or islet transplantation is the only cure for people with type 1 diabetes (T1D) and, due to
the autoimmune nature of the disease, MSCs have been utilised either natively or transdifferentiated into insulin-
producing cells (IPCs) as an alternative treatment. However, the initial success in pre-clinical animal models has not
translated into successful clinical outcomes. Thus, this review will summarise the current state of MSC-derived
therapies for the treatment of T1D in both the pre-clinical and clinical setting, in particular their use as an
immunomodulatory therapy and targets for the generation of IPCs via gene modification. In this review, we
highlight the limitations of current clinical trials of MSCs for the treatment of T1D, and suggest the novel clustered
regularly interspaced short palindromic repeat (CRISPR) gene-editing technology and improved clinical trial design
as strategies to translate pre-clinical success to the clinical setting.
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Background
Type 1 diabetes (T1D) results from an organ-specific
autoimmune-mediated loss of insulin-secreting β cells in
the pancreas. People with T1D manage their blood glu-
cose levels using exogenous insulin therapy; however,
this does not eliminate the development of long-term
diabetic complications such as retinopathy, nephropathy,
and neuropathy [1]. In addition, life-long use of exogen-
ous insulin increases the risk of hypoglycaemic unaware-
ness which can be potentially life-threatening.
Currently, pancreas or islet transplantation remains
the only cure; however, these treatments are limited by a
shortage of donor organs and the requirement for life-
long immunosuppression [2]. An alternative to current
therapies has been the generation of surrogate β cells
from a variety of tissue sources via chemically or genet-
ically induced transdifferentiation [3–10]. However,
many surrogate β-cell solutions that are derived from
cells such as induced pluripotent [7] and embryonic
stem cells [11] are susceptible to allorejection or recur-
rent autoimmunity. Thus, long-term survival of trans-
planted cells requires encapsulation which does not
necessarily provide immune protection in all cases. Due
to their high plasticity, immunomodulatory properties,
and fewer ethical concerns, mesenchymal stem cells
(MSCs) are an attractive alternative target cell for the au-
tologous and allogeneic treatment of T1D without the re-
quirement for encapsulation. In addition, early studies
demonstrating the ability of MSCs to differentiate into
insulin-producing cells (IPCs) via ex vivo chemical induc-
tion [6–10] or various gene therapy approaches [12, 13]
qualifies them as ideal candidates for cell transplantation.
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The purpose of this review is to highlight the success
of MSC-derived therapies in pre-clinical models of dia-
betes and reflect on the failure of the translation of these
studies into the clinical setting. We therefore suggest the
utilisation of clustered regularly interspaced short palin-
dromic repeat (CRISPR) and implementing improved
clinical trial design for the future success of T1D MSC-
derived therapies.
MSCs as an immunomodulatory therapy for T1D
Within the context of T1D, MSCs have been assessed
for use as an immunomodulatory therapy in small ani-
mal models of diabetes such as non-obese diabetic
(NOD) mice [14–16] and streptozotocin (STZ)-induced
diabetic animals [17, 18], where improvements in the
glycaemic control of treated animals have been observed.
Through these early studies, MSC interventions demon-
strated improved T1D outcomes through two mecha-
nisms: (i) MSC migration to areas of pancreatic injury
and modification of the islet microenvironment to pro-
mote the survival and regeneration of surviving β cells;
and (ii) abrogating inherent autoimmunity against β cells
[19]. In addition, MSCs can be co-transplanted with
pancreatic islets, thereby protecting the islets from allo-
geneic immune responses [20]. The success of MSC in-
fusions in pre-clinical animal models of diabetes are
summarised in Table 1.
MSCs promote the survival and regeneration of existing β
cells
Since MSCs are capable of modifying the tissue micro-
environment, MSC infusions can promote the survival
and regeneration of existing β cells, leading to increases in
β-cell mass and restoration of normoglycaemia [21–24].
In fact, following intravenous injection of MSCs into dia-
betic mice, increases in insulin levels and reduced hyper-
glycaemia were observed. Similarly, a single treatment of
umbilical cord-MSCs in humans provided lasting reversal
of autoimmunity that allowed regeneration of islet β cells
and improvement in glycaemic control [25–28]. However,
the success of such interventions is closely related to the
time from diagnosis. In many cases, people with long-
standing T1D would possess very little to no remaining β
cells, and consequently would unlikely be capable of re-
generating sufficient quantities of de novo β cells to ameli-
orate their hyperglycaemia.
MSC modulation of autoimmunity
As previously mentioned, MSCs possess wide-ranging
modulatory effects on immune cells, and therefore their
use in abrogating autoimmune diseases has been well
documented. The autoimmune nature of T1D unsurpris-
ingly ignited interest in the use of MSCs as a potential
cell therapy. Several pre-clinical diabetic animal studies
showed that transplantation of MSCs results in gly-
caemic restoration as a consequence of suppressed T-
cell proliferation and increased T regulatory cell (Treg)
presence within pancreatic islets [14–18]. In a recently
published clinical trial, MSCs injected through liver
puncture successfully reduced the levels of islet-cell anti-
bodies, glutamic acid decarboxylase, and insulin anti-
bodies of two patients in 12 months, suggesting
immune-modulated cell tolerance [29].
Pancreatic islet and MSC co-transplantation
Alternatively, MSCs recruit and increase the numbers of
immunosuppressive host cells during co-transplantation
of islets to promote graft survival. Specifically, following
human islet transplantation in an advanced humanized
mouse model, human bone marrow-derived MSCs
(BMSC) increased quantities of Tregs and caused im-
mune tolerance of the transplanted islets [20]. In fact,
the co-transplantation of MSCs and pancreatic islets was
able to achieve a state of normoglycaemia in diabetic
rats likely via MSC trophic factor secretion which pro-
tected the transplanted islets [30]. In addition, MSCs in
close contact with pancreatic islets began to express
Pdx-1 (pancreatic and duodenal homeobox-1, a funda-
mental transcription factor in β-cell development) and
to differentiate into IPCs.
The collective results of these pre-clinical studies
[14–18, 20, 30] demonstrate the success of MSCs as
an immunomodulatory cell therapy for the treatment
of T1D. Nevertheless, solutions are required to over-
come the challenge of the loss of immunosuppressive
characteristics over time and the requirement for high
cell doses. In addition, the fact that animal studies
have shown that MSCs derived from diabetic sources
were unable to suppress immune responses in animals
with diabetes raises concern over the utility of autolo-
gously sourced MSCs [31], potentially limiting the
isolation of MSCs to allogeneic sources.
MSCs as targets for the generation of IPCs
Ex vivo generation of IPCs is commonly performed via
differentiation of precursor/stem cells using unique
chemical regimens [6–10]. Alternatively, IPCs can be
generated via viral-mediated gene transfer resulting in
the transdifferentiation of lineage-committed cells [3–5].
Currently, encapsulation of IPCs is necessary to prevent
recurrent autoimmune destruction or allorejection [32].
Although micro-encapsulation technology for the most
part protects IPCs from CD4+ T cell-mediated destruc-
tion, these capsules are not impervious to cytokine-
induced apoptosis. MSCs are an attractive target for
generating IPCs due to their reported immune-
modulatory properties. Potentially, IPCs generated from
MSCs may retain some MSC-like qualities that could
Gerace et al. Stem Cell Research & Therapy  (2017) 8:62 Page 2 of 10
Table 1 Summary of the major MSC-derived studies in pre-clinical animal models of T1D
Treatment type Intervention Outcomes Fresh/frozen Reference
Immunomodulation Mice received 1 × 106 AD-MSCs by i.p.
injection
Reversal of hyperglycaemia characterised by increased
serum insulin, amylin, and GLP-1 levels. Downregulation
of the CD4+ Th1-based immune response and expansion
of Tregs in the pancreatic lymph nodes.
Fresh [13]
Mice received 1 × 105 MSCs either i.p.
or i.v.
Reduced infiltration of T cells to pancreatic islets
associated with preferential migration of MSCs to
pancreatic lymph nodes.
Fresh [14]
Mice received 0.5 × 106 MSCs administered
systemically
Reduced blood glucose levels and an increase in
morphologically normal pancreatic islets.
Fresh [16]
Rats received 2–4 × 106 MSCs via tail vein
injection
Enhanced insulin secretion and sustained
normoglycaemia. Islets from treated rats
co-expressed high levels of Pdx-1 and insulin.
Fresh [17]
Mice received a co-transplantation of
primary hBMSCs and human islets at
serial ratios under the kidney capsule
Good blood glucose control and increased
levels of serum insulin and C-peptide when
islets were co-transplanted with hBMSCs.
hBMSCs also increased the percentage of Tregs
and prevented cytokine-induced loss-of-function
of transplanted islets.
Fresh [19]
Mice received 5 × 105 MSCs injected
i.v. once a week for 4 weeks
BALB/c-MSC trafficked to the pancreatic lymph nodes of
treated animals. Administration of BALB/c-MSC temporarily
resulted in reversal of hyperglycaemia in 90% of treated
animals.
Fresh [30]
IPC differentiation Chemical differentiation BMSCs formed islet-like clusters containing IPCs that
expressed multiple pancreatic genes. The clusters
released insulin in a glucose-dependent manner and
ameliorated diabetes in STZ-treated nude mice.
Fresh [6]
Chemical differentiation BMSCs differentiated into IPCs and acquired islet-like
architecture after transplantation, developed an
endocrine gene expression profile and demonstrated
glucose-responsive insulin secretion. Subcapsular renal
transplantation of these aggregates lowered circulating
blood glucose levels.
Fresh [8]
Chemical differentiation Differentiated BMSCs expressed multiple pancreatic
genes and exhibited glucose-responsive insulin secretion.
Transplantation into STZ-diabetic mice imparted reversal of
hyperglycaemia and an improved IPGTT.
Fresh [9]
Chemical differentiation Differentiation cells expressed pancreatic genes and
displayed glucose-responsive insulin secretion.
Transplantation of differentiated cells into diabetic rats
reduced blood sugar levels.
Fresh [33]
Viral-mediated differentiation Differentiated cells expressed all four islet hormones and
demonstrated glucose-responsive insulin secretion. Cell
transplantation into STZ-diabetic immune-deficient mice
resulted in further differentiation, including induction of
NeuroD1 and reduction of hyperglycaemia.
Fresh [11]
Viral-mediated differentiation hMSCs differentiated into IPCs that expressed multiple
islet genes and released insulin/C-peptide in a weak
glucose-responsive manner. Upon transplantation into
STZ-diabetic mice, normoglycaemia was obtained within
2 weeks and maintained for at least 42 days.
Fresh [12]
Viral-mediated differentiation Differentiated AD-MSC expressed some islet genes and
secreted increasing amounts of insulin in response to
increasing concentrations of glucose. Transplantation
in STZ-diabetic rats resulted in lowered blood glucose
and higher glucose tolerance.
Fresh [36]
Viral-mediated differentiation Expression of Pdx1 in AD-MSCs did not induce the
pancreatic phenotype in vitro. Upon transplantation,
the cells engrafted in the pancreas, wherein they
expressed insulin and C-peptide, significantly decreased
blood glucose levels, and increased survival.
Fresh [37]
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eliminate the need for encapsulation. Currently, there
are two methods of generating IPCs from MSCs: chem-
ically induced and viral-mediated transdifferentiation.
Chemically induced transdifferentiation
Deriving IPCs from stem cells has most commonly been
performed by adapting in vitro transdifferentiation proto-
cols to yield high numbers of fully functional IPCs [6, 7].
IPCs can be obtained from MSCs via the use of high-
glucose culture medium [8, 9] or nicotinamide-enriched
medium to induce transdifferentiation [10]. The resulting
differentiated cells express insulin at both the mRNA and
protein level, and ameliorate hyperglycaemia in STZ rats
[10]. Similarly, BMSC isolated for expression of primitive
stage-specific embryonic antigen-1 (SSEA-1) and a num-
ber of MSC markers such as CXC, octamer-binding tran-
scription factor-4, and stem cell antigen-1 were induced to
differentiate into IPCs in defined transdifferentiation
medium [11]. These SSEA-1+ cells could further differen-
tiate into islet-like clusters that stained positive with dithi-
zone staining and were capable of secreting insulin in a
glucose-responsive manner. MSCs derived from alterna-
tive tissue sources have also been subjected to similar
chemically defined transdifferentiation protocols that re-
sulted in the successful generation of IPCs [33, 34].
Viral-mediated transdifferentiation
Viral-mediated gene transfer has been investigated as a
method to re-introduce normal copies of DNA into abnor-
mal cells, or other cell types, as a means of treating genetic
diseases for some time. Ideally, β-cell engineering would
employ integrating viral vectors that provide sustained
therapeutic gene expression over the life of the patient. To
this end, viral-mediated transdifferentiation is an attractive
method of obtaining surrogate β cells as they would be less
likely to express identical autoantigens against which the
primary autoimmune response was developed. Since tran-
scription factors play a significant role in determining
islet-cell fate during pancreatic embryogenesis, our labora-
tory and many others have investigated the direct transfer
of β cell transcription factors and insulin as mediators of
pancreatic transdifferentiation [3–5, 35].
Due to the success of gene transfer in generating IPCs
from a number of cell types, and the requirement for
encapsulation to translate basic research into the clinical
setting, MSCs have become an attractive target for com-
binatorial gene and cell therapy. Consequently, several
studies were performed investigating the ex vivo targeting
of MSCs for viral-mediated transdifferentiation into IPCs.
A study by Karnieli et al. utilised retrovirus for the trans-
duction of BMSCs with the key pancreatic transcription
factor Pdx-1, resulting in glucose-responsive production
of insulin [12]. Furthermore, when these cells were trans-
planted under the renal capsule of STZ-diabetic SCID
mice, they reduced blood glucose levels for a period of 6–
8 weeks, after which abnormal glucose tolerance was ob-
served. In fact, Pdx-1 has been delivered to a number of
tissue-specific MSCs, including BMSCs [13] and adipose-
derived MSCs [36, 37] with varying success in generating
glucose-responsive IPCs. Despite the early success with
Pdx-1, some studies have shown that Pdx-1 induced exo-
crine transdifferentiation, resulting in the development of
hepatitis and an increased likelihood of autoimmune de-
struction [35]. Thus, alternative choices of transcription
factors were assessed for their ability to induce pancreatic
transdifferentiation without exocrine transdifferentiation.
One study in particular found that NeuroD1-betacellulin
delivery resulted in no hepatotoxicity, identifying NeuroD1
as an ideal alternative for IPC generation [35]. These re-
sults were verified by our laboratory, where the transduc-
tion of the H4IIE rat liver cell line with rat NeuroD1 and
INS-FUR induced pancreatic transdifferentiation charac-
terised by expression of β cell transcription factors,
glucose-stimulated insulin secretion, and reversal of dia-
betes upon transplantation in STZ-diabetic mice [38].
Insulin transfer to MSCs has been performed less
often, most likely due to the fact that ex vivo transfer of
insulin alone is insufficient to induce pancreatic transdif-
ferentiation, and most commonly results in constitutive
insulin secretion. Xu et al. studied the retroviral trans-
duction of BMSCs expressing the human insulin gene
under the control of the cytomegalovirus (CMV) pro-
moter and the ability of these transduced cells to restore
normoglycaemia in STZ-diabetic mice [39]. The results
showed that BMSCs successfully expressed insulin and
were able to maintain normoglycaemia for at least
42 days. In addition, transduced BMSCs were able to
evade autoimmune destruction that ordinarily targets
Table 1 Summary of the major MSC-derived studies in pre-clinical animal models of T1D (Continued)
Viral-mediated differentiation Body weight in diabetic mice that received
GFP-mMSCs expressing the human insulin
gene was increased by 6% within 6 weeks
after treatment.
Fresh [39]
AD-MSC adipose-derived mesenchymal stem cell, BMSC bone marrow mesenchymal stem cell, CD cluster of differentiation, GFP green fluorescent protein, GLP-1
glucagon-like peptide 1, hBMSC human bone marrow mesenchymal stem cell, i.p. intraperitoneal, IPC insulin producing cell, IPGTT intraperitoneal glucose tolerance
test, i.v. intravenous, MSC mesenchymal stem cell, Pdx-1 pancreatic and duodenal homeobox 1, STZ streptozotocin, Tregs regulatory T cells, mMSC murine mesen-
chymal stem cell, BALB/c-MSC Bagg Albino mesencymal stem cells
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pancreatic islets. However, similar efforts utilising
adeno-associated virus (AAV) and retroviral vectors have
resulted in constitutive insulin secretion as a conse-
quence of the absence of glucose transporter 2 (GLUT2)
and islet glucokinase gene expression. This feature
would only develop following transdifferentiation rather
than forced insulin expression. Thus, induction of pan-
creatic transdifferentiation for the production of IPCs
should be mediated via transfer of specific pancreatic
transcription factors, either alone or in combination, and
in addition to the expression of insulin. The success of
MSC-derived IPCs in pre-clinical animal models of dia-
betes is summarised in Table 1.
From pre-clinical success to clinical failure and the way
forward
Due to the success of MSC infusions and MSC-derived
IPCs in pre-clinical animal models of diabetes, several
human clinical trials have been undertaken or are cur-
rently in progress (Table 2). In translating pre-clinical
studies to the human clinical setting, many of those con-
ducting clinical trials have failed to consider the scien-
tific basis of MSC function that makes their use in the
pre-clinical setting so successful. Maintenance of MSC
function for successful clinical trials is highly linked to
choice of donor, preliminary ex vivo cell culture condi-
tions, cryopreservation, and post-storage culture condi-
tions, four caveats that have been overlooked and are a
hallmark of the current clinical failure of MSCs for the
treatment of T1D and other diseases.
MSC donor profiling and post-harvest expansion
In many clinical trials, MSCs are harvested from a single
donor, culture expanded, and cryopreserved prior to ad-
ministration to a trial participant. Donor variability is a
concern that requires careful assessment prior to har-
vesting MSCs for clinical trials, as phenotype, age, and
gender can affect MSC function and growth characteris-
tics [40]. Consequently, the choice of a suitable donor is
critical, as MSCs with a dampened immunomodulatory
profile are less likely to perform as well in vivo as MSCs
with a robust immunomodulatory profile. As such, pro-
filing of multiple donors for MSC immunomodulatory
function should be included as a necessary control step
prior to the utilisation of allogeneic MSC treatments.
Compounding single donor harvesting is the fact
that MSCs constitute a small proportion of the cellu-
lar fraction of the tissue from which they are sourced.
Thus, culture expansion is required to generate clinic-
ally sufficient quantities of MSCs for transplantation,
a process that results in phenotypic changes such as
a decrease in proliferative capacity and self-renewal.
In addition, doubts concerning the clinical application
of ex vivo cultured MSCs for immunomodulatory
therapies have been raised due to their apparent loss
of immunomodulatory properties with continued sub-
culture (in particular the downregulation of chemo-
kine receptors and reduction in secretion of soluble
factors). This is highlighted by the Prochymal® study
(Table 2) which pursued the off-the-shelf “one har-
vest, multiple therapies” concept, and ultimately failed
in the clinic due to the extensive ex vivo culture re-
quired. The major contributing factor to the success
or failure in pre-clinical vs clinical trials of MSCs is
that pre-clinical studies utilise freshly harvested MSCs
from either single or multiple animal donors followed
by immediate transplantation into the animals to be
treated. Minor cell expansions are acceptable; how-
ever ongoing expansion for upscaling of cell quan-
tities ultimately detrimentally affects MSCs in the
clinical setting. Reconstituting the downregulation of
MSC chemokine receptors and secreted factors via
gene transfer to prolong MSC immunomodulatory
properties for clinical therapies is a solution that
could prove beneficial, especially with regards to T1D
which requires a long-term therapeutic solution.
However, multiple gene transfer of exogenous genes
represents a logistical challenge that would render
such a therapy challenging to translate into the clinic.
Post-cryopreservation culture and administration
Naturally, storage of therapeutic cells is a crucial process
in conducting clinical trials. With trial participants re-
quired to travel long distances to receive treatment, the
need to preserve stocks of therapeutic cells in the in-
terim is imperative. Cryopreservation is the most popu-
lar form of cell preservation, and in the clinical setting is
a practical form of bio-banking. However, several studies
have shown that cryopreserved MSCs have an impaired
immunosuppressive profile in comparison to fresh
MSCs, explaining the failure of many clinical trials utilis-
ing cryopreserved, culture-expanded MSCs [41, 42]. This
feature is characterised by increases in expression of
heat shock proteins, a lack of interferon (IFN)-γ-medi-
ated indoleamine 2,3-deoxygenase (IDO) production and
a reduced immunosuppressive effect on T-cell popula-
tions. Interestingly, post-cryopreservation culture for
24 h reverses these effects [41]. As such, successful clin-
ical use of MSCs for the treatment of T1D (and many
other diseases) requires careful trial organisation, focus-
ing on the appropriate and responsible use of MSCs. In
future, regulation of critical processes such as donor
choice, minimal post-harvest expansion, and post-freeze
MSC culture could result in more successful clinical tri-
als that fulfil the promise of pre-clinical studies and that
of the exciting prospect of MSCs as a cellular therapy
for T1D.
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Table 2 Summary of the major clinical trials utilising MSCs as a treatment for T1D
Trial number Phase Intervention Outcomes Fresh/
frozen
Status Reference
NCT01068951 N/A Intravenous, autologous transplantation
of MSCs (approximately 2 × 106 cells/kg
body weight)
Patients in the control arm showed
losses in both C-peptide peak values
and C-peptide when calculated as
area under the curve during the first
year. In MSC-treated patients, these
responses were preserved or even





NCT01374854 1/2 1 × 106/kg UC-MSCs are infused through
the pancreatic artery along with BM-MNCs
by interventional therapy and another
same dose of UC-MSCs administered
1 week post-intervention
C-peptide increased 105.7% in 20
of 21 responders versus 7.7%
decrease in control subjects.
HbA1C decreased 12.6% in treated
versus 1.2% increase in control
subjects. Daily insulin requirements
decreased 29.2% in treated versus




NCT00703599 1/2 i.v. administration of autologous activated
stromal vascular fraction derived from
100–120 ml lipoaspirates following
mini-liposuction of abdominal adipose
tissue




NCT01219465 1/2 i.v transfusion of UC-MSCs (2 × 107 cells/kg
body weight)
No reported acute or chronic side
effects in MSC-treated versus saline
control. Both HbA1c and C-peptide
in MSC-treated patients were
significantly better than either
pre-therapy values or saline control






1/2 Human UC-MSCs within the Stem Cell
Educator device
A single treatment provided lasting
reversal of autoimmunity that allowed
regeneration of islet β cells and
improvement of metabolic control in
subjects with long-standing T1D
Fresh Recruiting [24–27]
NCT02057211 2 Transfusion of autologous MSC versus
sham MSC transfusion vs placebo control
N/A Fresh Recruiting N/A
NCT01143168 1 Multiple transplantation of BM-MNC +
UC-MSCs





NCT00646724 1/2 Co-transplantation of islet allograft and
MSC autograft




NCT01322789 1/2 Four consecutive intravenous infusions,
1 week apart, followed by four consecutive
infusions 1 month apart




NCT01496339 1/2 1 × 106/kg MenSCs are infused through the
pancreatic artery or intravenously once a
week in four consecutive therapies






NCT02644759 1/2 Transplantation of autologous CD34
+/CD133+ cells into the pancreatic artery
and capillaries via interventional radiology
techniques. Immunomodulation by
incubation of autologous UC-MSCs for
3–6 h, and return of autologous WBCs





NCT00690066 2 Intravenous infusion of ex vivo cultured
adult human MSCs vs placebo intravenous
infusion of excipients of PROCHYMAL®




NCT01157403 2/3 Intravenous autologous transplantation of
BMSC (approximately 2.5 × 106 cells/kg
body weight)




Clinical trial data was acquired from www.clinicaltrails.gov using the search terms “mesenchymal stem cells” and “type 1 diabetes”
BM-MNC bone marrow mononuclear cell, BMSC bone marrow-derived mesenchymal stem cell, CD cluster of differentiation, HbA1C glycosylated haemo-
globin, i.v. intravenous, MenSC menstrual blood mesenchymal stem cell, MSC mesenchymal stem cell, N/A not available, T1D type 1 diabetes, UC-MSC um-
bilical cord mesenchymal stem cell, WBC white blood cell
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CRISPR: a novel strategy to improve MSC therapy for T1D
In recent times, a novel gene-editing technology that
has caught the interest of scientists worldwide is the
class of RNA-guided endonucleases known as
CRISPR-associated protein 9 (Cas9) from the microbial
adaptive immune system known as CRISPR [43, 44].
Using short guide (sg)RNAs, the Cas9 endonuclease
can be guided to any genomic location, inducing
double strand breaks allowing for non-homologous
end joining or homologous recombination of genomes
at specific locations. By inactivating the catalytic ac-
tivity of the Cas9 endonuclease, a nuclease-deficient
Cas9 (dCas9) can be engineered. In fact, dCas9 fused
to transactivation domains such as VP64 or p300 can
subsequently be guided using target-specific sgRNAs
to the upstream promoter region of endogenous
genes, thereby upregulating gene expression [43, 44].
In addition, concerns regarding off-target effects are
not as pronounced by comparison to traditional
CRISPR applications due to the promoter-specific de-
sign of sgRNAs that possess less likelihood of un-
wanted activator recruitment to promoter regions of
non-target genes by chance.
Early studies showed that single sgRNAs targeted to
the promoter region of target genes activate negligible
levels of endogenous gene expression. However, mul-
tiplexing with three or more sgRNAs results in syner-
gistic activation of target genes with significant
increases in gene expression. More importantly,
sgRNA multiplexing can be designed for multiple
gene activation [45], thereby eliminating the need to
deliver multiple transcription factor cDNAs for robust
gene expression to induce differentiation. Improve-
ment in dCas9-transcriptional activator fusions have
led to novel gene activators with enhanced activation
capabilities compared to early dCas9-VP64 activators.
Fusions of dCas9 to multiple co-activators such as
the VPR domain (consisting of VP64, p65, and Rta),
or specifically engineered dCas9 proteins that utilize
modified sgRNAs in conjunction with a synergistic
activator complex have been shown to induce robust
gene activation [46]. In fact, several recent studies
have demonstrated CRISPR-mediated activation of en-
dogenous gene expression for controlled differenti-
ation into diverse cell types [47–49].
By utilizing dCas9 activators and multiple sgRNAs
to target the endogenous activation of pancreatic
transcription factors and/or MSC chemokine recep-
tors in MSCs, it may be possible to direct the differ-
entiation of MSCs into surrogate IPCs capable of
maintaining their immunomodulatory properties
through ex vivo expansion and transplantation (Fig. 1).
To this end, one study in particular has demonstrated
success in activating endogenous human insulin tran-
scription utilizing the dCas9-VP160 fusion and mul-
tiple insulin promoter targeting sgRNAs in HEK293T,
Hela, and human fibroblasts [50]. The success of this
study supports the proposed novel application of acti-
vating transcription of endogenous genes involved in
pancreatic development such as Pdx-1, Neurod1,
MafA, etc. When combined with the targeted activa-
tion and maintenance of genes involved in MSC
Fig. 1 CRISPR-mediated generation of IPC and enhanced MSC-derived immunotherapies. Expression of the nuclease-deficient dCas9 fused to a
transcriptional activator in MSCs facilitates the activation of endogenous gene expression. To drive the differentiation of MSCs into IPCs (blue
boxes), sgRNAs targeting the promoter of target genes such as Pdx-1, NeuroD1, MafA, etc., are delivered to MSCs expressing the dCas9-transcription
activator fusion. Additional sgRNAs targeting the promoter of genes involved in MSC immunomodulation (red boxes) are delivered in combination to
maintain the immunomodulatory phenotype of MSCs through multiple cell expansions for the development of therapeutic doses of cell therapy. CCL
chemokine ligand, CXCR chemokine receptor, dCas9 nuclease-deficient CRISPR-associated protein 9, GCG glucagon, IDO indoleamine 2,3-deoxygenase,
IFN interferon, IL interleukin, INS insulin, MafA v-maf musculoaponeurotic fibrosarcoma A, M-CSF macrophage colony stimulating factor, Neurod1
neuronal differentiation 1, Ngn3 neurogenin 3, Nkx6.1 NK6 homeobox 1, NOS nitric oxide synthase, Pdx1 pancreatic and duodenal homeobox 1,
sgRNA short guide RNA, SST somatostatin, VEGF vascular endothelial growth factor
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immunomodulation such as chemokine receptors and
soluble factor production, the likelihood of developing
successful MSC-derived therapies for T1D becomes a
realistic outcome (Fig. 2).
Conclusion
Both gene therapy and stem cell therapy have proven
to be successful avenues for the development of a
treatment for T1D. In vitro and in vivo studies have
shown that both systems have the potential to be de-
veloped further, either individually or in combin-
ation. Although MSCs have been shown to be
successful in treating T1D by modulating the pan-
creatic islet microenvironment and immune re-
sponses in preclinical and clinical studies, a
sustained therapeutic effect is yet to be observed.
Similarly, the use of IPCs generated from autologous
MSCs to reverse T1D is limited by several challenges
such as recurrent autoimmunity, obtaining sufficient
numbers of IPCs for transplantation, and loss of im-
munomodulatory properties. Ultimately, the use of
MSC-derived therapies for the treatment of T1D re-
quires appropriate manufacturing conditions that do
not impinge on the function of MSCs prior to ad-
ministration. Clinical success will require persever-
ance and realistic translation of pre-clinical
methodology, without pushing the applicable limits
of these therapies.
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differentiation 1; NOD: Non-obese diabetic; Pdx-1: Pancreatic and duodenal
homeobox-1; sgRNA: short guide RNA; SSEA-1: Stage-specific embryonic
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